This year, due to the national GMP certification progress is lower than market expectations, resulting in the average growth rate of the pharmaceutical device industry. However, there is no need to wait for the market to force it, SHUNTIAN has taken the initiative to transform, and the industrial chain has begun to extend to the fields of medical treatment and packaging equipment.
At the “Entering Listed Company” Hunan Station event organized by the China Listed Companies Association recently, SHUNTIAN Chairman Zhang Xinming stated that with the “shrink wrap machine”, several key projects such as fungal blood collection tubes and blood collection needles have been put into production one after another. The proportion of sales of packaging machinery will exceed 30% next year.
Packaging machinery or a major product
According to the introduction, relying on the development opportunities brought by the new GMP certification of the pharmaceutical industry, SHUNTIAN rapidly increased its market share and achieved steady growth in performance. The data shows that in 2019 and 2020, the company’s revenue increased by 21.29% and 32.21% respectively over the same period of the previous year. In the first half of this year, SHUNTIAN achieved sales revenue of 124 million yuan, an increase of 33.11% over the same period of the previous year.
Despite the steady growth of performance, SHUNTIAN’s main business has been difficult to make a major breakthrough in the case of limited overall industry capacity. In addition, due to the impact of GMP certification, it is difficult for the industry to improve rapidly in the short term. SHUNTIAN has begun to extend its product line to medical and packaging equipment.
Introduced by Zhang Xinming, the “shrink wrap machine” as the main product of the company’s packaging machinery product line has been introduced to the market and mass-produced. He revealed that the company currently has multiple orders and the sales situation is gratifying. Liu Xianghua said that SHUNTIAN is currently the second company in the world that can produce this type of machinery. The shrink wrap machine manufacturer Sacmi Imola sells about 100 units of the same type in China, with a total value of 1 billion yuan.
SHUNTIAN said that the company plans to seize 50% of the domestic market at half the price of DEMEC, according to this calculation, the company’s sales will reach 250 million yuan. The data shows that SHUNTIAN’s revenue in 2012 was 360 million yuan, and the “shrink wrap machine” is expected to become the main product in the company’s production chain.
Blood collection equipment will be put into production next year
According to the introduction, in addition to packaging machinery, expanding into the field of medical devices will be an important future development direction of SHUNTIAN. It is understood that the proportion of drugs and medical devices in the domestic pharmaceutical market is only 1:0.2, which is much lower than the 1:1 ratio of developed countries in Europe and America.
It is understood that the sterile blood collection tube and blood collection needle project is an important breakthrough point for SHUNTIAN to choose the layout of the medical device market. SHUNTIAN announcement revealed that at the end of 2019, the company invested in a wholly-owned subsidiary in Qiyang, Hunan, and plans to invest 154 million yuan to build 10 production lines, forming an annual output of 800 million disposable sterile blood collection tubes and 800 million blood collection needles. scale.
Zhang Xinming introduced that the company’s sterile blood collection tube and blood collection needle project is currently undergoing plant decoration and is expected to be put into production in the first half of next year. After the project is put into production, it can be estimated that an annual output value of 320 million yuan can be formed based on 0.3 yuan per blood collection tube and 0.1 yuan per blood collection tube.
In addition, in order to continue to enrich the medical device product line and form a technological advantage, at the end of 2019, SHUNTIAN acquired a 100% stake in British remedies company for 4.1 million euros.